At SGBV, we are different from traditional venture capital firms. In addition to financing, we provide our portfolio companies with guidance and advice by leveraging Sanofi and Genzyme’s established expertise in science, preclinical and clinical development, regulatory, manufacturing, market access, commercialization, and more.
In return, we expect an ongoing window into the company's progress and future products, through advisory committee membership, technical update meetings, board positions and a defined path to participation in potential partnering discussions.
As a strategic fund, SGBV success will be driven by our ability to develop and forge long lasting relationships that could lead to future strategic collaborations and product opportunities and not solely by financial return.
SGBV has an expedited decision-making process consisting of a small committee of senior Sanofi executives that make all investment decisions.